Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07587216

Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment

This study is a prospective, observational, real-world cohort study. We aim to establish a prospective database in the Department of Hepatobiliary and Pancreatic Surgery, systematically collecting and integrating patients' full-course diagnostic and therapeutic information along with long-term outcomes. This will enable objective evaluation of prognosis and treatment efficacy in real-world clinical practice, while providing a data foundation and evidence support for subsequent optimization of clinical decision-makin

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Liver Cancer (Primary and Metastatic) Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasm Metastasis Neoplasms Neoplasms by Site Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

Location status: Recruiting

Location contact

Qi Cheng, M.D.

CONTACT

[email protected]

13871459541

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female aged ≥18 years at the time of signing the informed consent form
  • Clinically or histologically confirmed diagnosis of liver cancer
  • Recieving treatment and follow-up in Tongji Hospital

Exclusion criteria

  • Refuse participanting in this study

Treatment and study plan

liver resection

Procedure

Patients undergo liver resection for tumor.

Systemic therapy combined with locoregional interventions

Drug

Patients recieve PD-1 inhibitors combined with targeted drugs and locoregional interventions

Primary outcomes

  1. overall survival

    Time frame: From date of treatment until the date of death from any cause, assessed up to 100 months

Secondary outcomes

  1. Incidence of Adverse Events

    Time frame: Within 30 days following interventions

Study contacts

Contact information is provided by the study sponsor or research team.

Qi Cheng, M.D.

CONTACT

[email protected]

13871459541

Sponsors and collaborators

Lead sponsor

Tongji Hospital

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2029
First posted
May 14, 2026
Registry last updated
Jun 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.